english.prescrire.org

Welcome to the Prescrire in English website

Reliable, rigorously independent information on treatments and healthcare strategies,
to enable fully informed decision-making. Prescrire is financed by its subscribers.
No grants, no advertising. No shareholders, no sponsors.

In Prescrire's Spotlight

"Biosimilars": towards fewer obstacles to their use

1 March 2015

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
In the March issue of Prescrire International: Drugs to avoid in 2015

1 March 2015

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Multiple sclerosis: neither natalizumab nor alemtuzumab

1 March 2015

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Teriflunomide (Aubagio°) is or will soon be on the market in several countries

1 March 2015

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Prescrire's Drug Awards for 2014: a good vintage

1 February 2015

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Prescrire's Drug Packaging Awards for 2014: one winner, but still too many dangerous flaws

1 February 2015

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Prescrire's annual Information Awards: several firms are commended, but too many have underperformed

1 February 2015

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Receive the free, monthly "Independent Drug & Healthcare Newsletter"

1 November 2014

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Subscribe online for full access to content from Prescrire International

1 December 2014